Aislinn Antrim, Assistant Managing Editor

Annual Asembia summit features insights from key opinion leaders, networking events, and continuing education sessions for pharmacists, pharmacy staff and stakeholders.

A severe reduction in food intake lasting just 2 weeks caused damage to the heart and kidneys that appeared to be irreversible, even after the body weight was restored.

Poor sleep efficiency may contribute to vascular dysfunction with increasing exposure to adverse childhood experiences.

The number of female study participants was lower when the last author of the study, usually the head of the lab conducting the study, was a man.

All-cause inpatient mortality or discharge to hospice was lower for patients who received dexamethasone within 48 hours of either admission or escalation in oxygen support.

In a phase 3 trial, the risk of disease progression, relapse, or death was reduced by 27% with polatuzumab vedotin-piiq plus R-CHP compared with R-CHOP in adults with previously untreated diffuse large B-cell lymphoma or high-grade B-cell lymphoma.

Atypical respiratory syncytial virus epidemics may continue, and testing patients for multiple respiratory pathogens when indicated might be necessary.

The findings could inform revisions to safety guidelines and policies that help protect people with cardiovascular issues during heat waves.

Multicancer early detection test could detect cancer with an AUC of 0.94 for all cancer types and stages.

The efficacy and tolerability of rizatriptan for acute migraine treatment has been well established.

Respiratory syncytial virus (RSV) vaccine demonstrated efficacy of 66.7% in reducing RSV-associated lower respiratory tract illness with at least 2 signs or symptoms in older adults.

Based on the study results, investigators concluded that there is justification for a randomized clinical trial.

The risk of a second stroke after intracerebral hemorrhage (ICH) did not differ by index hematoma location, and this risk was higher for ischemic stroke than ICH.

During the 12-month trial period, Hyqvia was shown to be efficacious treating the occurrence of acute serious bacterial infections in children aged 2 through 16 years with primary immunodeficiency.

Availability of clinical trials in the gynecologic cancer care space are increasing, but it is important to be mindful of current racial disparities.

The risk is particularly high in the first 2 years after an HIV diagnosis.

It is still unclear whether comorbidities have similar negative effects on cognition beyond those directly caused by obstructive sleep apnea.

Taken together, the studies point to meaningful changes in the standard of care for patients with advanced or recurrent endometrial cancer.

The trial did not meet the second primary efficacy endpoint of medically attended respiratory syncytial virus-associated lower respiratory tract illness.

The overall survival hazard ratio numerically favored niraparib in the germline BRCA mutation cohort and favored placebo in the non-germline BRCA mutation cohort in patients with platinum-sensitive recurrent ovarian cancer.

Among those without HIV, the analyses found that respondents with a history of COVID-19 performed worse on processing speed than those who had never had COVID-19.

The application is based on the PHAROS trial, which met its primary endpoint of objective response rate in patients with metastatic non–small cell lung cancer with a BRAF V600E mutation.

Students still have a myriad of career options, including at retail pharmacies, hospitals, and outside traditional practice.

Improvements in progression-free survival were seen in patients with advanced or recurrent endometrial carcinoma regardless of mismatch repair status.

Key lifestyle risk factors for chronic diseases and cancers include tobacco use, poor nutrition, lack of physical movement, and obesity.

Presenter at the 2023 Community Oncology Alliance meeting notes that oncology has become more of a duality between molecular and genetic subsets, leading to huge developments in targeted and personalized care.

Among patients with lung cancer, approximately 20% have the earliest stage of disease but are still dying of metastatic lung cancer within about 5 years.

Drugs such as pembrolizumab, sacituzumab govitecan, and datopotamab deruxtecan all have growing bodies of evidence illustrating which patients with cancer are most likely to benefit and in which settings.

Despite tensions that can occur, building relationships with health systems and finding opportunities to collaborate is crucial to improve cancer care.

Sandoz intends to launch the latest Humira biosimilar in the United States on July 1, 2023.